Anecova is a life science company focused on the development and commercialization of novel technologies in the field of Assisted Reproductive Technologies (ART). Our goal is to improve the overall quality of care in ART by enabling the use of more physiologic and natural processes.

The first Anecova product aims to restore the fertilization and early development of the embryos to the natural environment of the maternal womb. Thanks to this technology the embryos can start their life in close communication with the maternal environment. The expected result of the culture of embryos in the womb is a higher number of quality embryos, thus a better overall result for the assisted reproductive cycle. The preliminary results are encouraging.

Anecova is therefore currently undertaking further clinical evaluation in close collaboration with international experts in the field with the goal of bringing a strong improvement to the assisted reproductive experience of patients worldwide.